Clin2
NCT02870244Possibly a fitRecruiting

Engineered T-cell therapy for advanced melanoma patients

Melanoma

Part of Cancer, Skin clinical trials.

This Phase 1 study tests a lab-made immune cell treatment for advanced melanoma. It aims to see if engineered T-cells can recognize the patient’s tumor and help control the cancer, especially in specific melanoma tissue markers.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
18 years to 89 years
Study type
Interventional

Who can take part

  • You have melanoma that has spread (metastatic) and can be measured on scans or exams
  • You are 18 or older and can sign consent before any study tests
  • Your health and daily function are good (ECOG performance status 0–1)
  • Your tumor tissue tests positive for both tyrosinase and HLA-A2 (from a biopsy)
  • Your heart pumping strength is normal for the study (ejection fraction above 50%)
  • You are not currently pregnant or breastfeeding, and you can use effective birth control

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06204991Recruiting· Phase 1
T-cell therapy for advanced melanoma

This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.

Herlev
NCT02621021Recruiting· Phase 2
Immune cell therapy for advanced melanoma

This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.

Bethesda, Maryland
NCT06739226Not yet recruiting· Phase 1/Phase 2
Combination Immunotherapy for Advanced Melanoma

This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.

Shenzhen, Guangdong
NCT06961357Recruiting· Phase 1/Phase 2
CD40L-Enhanced TIL therapy for advanced melanoma

This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.

Tampa, Florida
NCT07028008Not yet recruiting
TIL therapy for advanced melanoma after immunotherapy

This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.

NCT06212388Not yet recruiting· Early Phase 1
Cell therapy plus immunotherapy for removable melanoma

This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.

Hear when a new Melanoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.